Cerebral Embolic Protection: Is There a Benefit for Left Atrial and Mitral Valve Procedures?
- Open Access
- 07-10-2024
- Transcatheter Mitral Valve Replacement
- Interventional Cardiology (SR Bailey and T Helmy, Section Editors)
- Authors
- Besir Besir
- Samir R. Kapadia
- Published in
- Current Cardiology Reports | Issue 12/2024
Abstract
Purpose of Review
This review aims to highlight the current evidence on the use of cerebral embolic protection devices (CEPD) in left atrial and transcatheter mitral valve procedures. It also aims to summarize the antithrombotic management of patients undergoing such procedures.
Recent Findings
Ischemic stroke is one of the most devastating complications of structural heart procedures. The manifestation of periprocedural stroke can range from asymptomatic and detectable only through brain imaging to major stroke with neurological deficits. CEP devices were initially developed to mitigate the risk of stroke associated with transcatheter aortic valve replacement (TAVR). However, the efficacy of such devices during different cardiac interventions is yet to be fully demonstrated, especially in left atrial appendage closure (LAAO), and mitral valve interventions. Few studies demonstrated that the risk of periprocedural strokes after LAAO and mitral valve interventions is not negligible and is highest during the periprocedural period and then falls. The majority of patients undergoing those procedures have cerebral ischemic injuries detected on diffusion-weighted magnetic resonance imaging (DW-MRI). Moreover, a reasonable number of those patients had debris embolization on the filters of the CEPD. Pharmacological therapy with antithrombotic agents before, during, or after structural heart interventions is crucial and should be tailored to each patient’s risk of bleeding and ischemia. Close monitoring that includes a full neurological assessment and frequent follow-up visits with cardiac echocardiography are important.
Summary
The risk of periprocedural stroke in left atrial and transcatheter mitral valve procedures is not negligible. Pharmacological therapy with antithrombotic agents before, during, or after structural heart interventions is important to mitigate the risk of stroke, especially the long-term risk. More prospective studies are needed to assess the efficacy of CEPD in such procedures.
Advertisement
- Title
- Cerebral Embolic Protection: Is There a Benefit for Left Atrial and Mitral Valve Procedures?
- Authors
-
Besir Besir
Samir R. Kapadia
- Publication date
- 07-10-2024
- Publisher
- Springer US
- Keywords
-
Transcatheter Mitral Valve Replacement
Oral Anticoagulant
Direct Oral Anticoagulant
Direct Oral Anticoagulant
Stroke - Published in
-
Current Cardiology Reports / Issue 12/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170 - DOI
- https://doi.org/10.1007/s11886-024-02132-4
This content is only visible if you are logged in and have the appropriate permissions.